Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)

• Status: Recruiting
• Trial end date: 2023-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators seek to demonstrate that the combined use of cilostazol and nimodipine will significantly decrease the rate of delayed cerebral infarction and cerebral vasospasm after cerebrovascular intervention when compared to nimodipine alone.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ascension South East Michigan
• Treatments: Cilostazol; Nimodipine

Criteria

Inclusion Criteria:

• 18 years of age or older

• Anterior circulation aneurysm

• Patients who have undergone surgical intervention

• Absence of rebleeding or new intracranial hemorrhage noted on post-intervention CT scan

• Consent for study participation

Exclusion Criteria:

• Non-aneurysmal subarachnoid hemorrhage

• Multiple ruptured aneurysms

• Patients with congestive heart failure

• Severe aneurysmal subarachnoid hemorrhage (Hunt Hess Grade V)

• Active pathological bleeding

• Allergy to cilostazol

• Positive pregnancy test

• Coagulopathy not caused by anti-coagulant use

• History of hemorrhagic complications (gastrointestinal bleeding, etc)

• Uncontrolled or severe comorbidity that would qualify as an absolute contraindication for cilostazol

• Patients requiring anticoagulant/antiplatelet treatment following intervention (e.g. stent-assisted coiling or flow-diverting stent obliteration of aneurysm)